Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model

Zhiwei Huang, Wenfang Li, Ruohao Zhang, Yi Li, Xin Li, Xingchen Bian, Shansong Zheng, Xinmei Wang, Ning Zhang, Gao Cong, Beining Guo, Zhenling Wang, Jing Zhang, Xiaojie WuFrontiers in Microbiology 2024 · DOI

Abstract: These PK/PD data derived from mouse thigh infection models will be used to inform the optimal dosing regimen of pralurbactam/meropenem combination in clinical trials.

Introduction

The rise of multidrug-resistant "superbugs," particularly carbapenem-resistant Enterobacterales (CRE), has rendered many potent antibiotics ineffective. Bacteria defend themselves primarily by producing $\beta$-lactamases—enzymes that neutralize antibiotics like meropenem. Pralurbactam (FL058) is a novel diazabicyclooctane $\beta$-lactamase inhibitor (BLI) designed to inhibit a broad spectrum of these enzymes, including Classes A, C, and D. To use it effectively in humans, researchers must understand the relationship between the drug's concentration over time (pharmacokinetics) and its ability to kill bacteria (pharmacodynamics).

Methodology and Datasets

The researchers employed a neutropenic murine thigh infection model, a standard in antibiotic research. Mice were rendered immunocompromised to ensure results reflected drug efficacy rather than the animal's immune response. Thighs were inoculated with clinical isolates of Klebsiella pneumoniae and Escherichia coli expressing various resistance enzymes (e.g., KPC-2, OXA-48, NDM-1, NDM-5).

Mice received meropenem alone or in combination with pralurbactam using various dosing frequencies (every 2, 4, or 8 hours) to perform dose-fractionation and dose-escalation studies. Drug levels in plasma were measured using ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The team used a sigmoid $E_{max}$ model to correlate three PK/PD indices—$fC_{max}$ (peak concentration), $fAUC$ (total exposure), and %$fT > C_T$ (time above a threshold concentration)—with bacterial load changes.

Pharmacokinetic Profile and Linearity

Pralurbactam demonstrated a linear pharmacokinetic (PK) profile in mice, meaning plasma concentration increased proportionally with the dose. This linearity simplifies dosing predictions for human trials. The drug followed a one-compartment model with a mean half-life that allowed for clear dose-response analysis.

Figure 1: Pralurbactam plasma concentration-time curves after intraperitoneal injection of single ascending doses of pralurbactam alone or combined with meropenem.

Key PK/PD Targets and Results

Among the indices tested, %$fT > 1$ mg/L was the best predictor of efficacy ($R^2 = 0.733$), suggesting that maintaining a steady "floor" concentration is more important than achieving high peaks. The study successfully quantified the targets required for bacteriostasis and a 1-log10 reduction in bacteria:

  • For K. pneumoniae: Bacteriostasis required %$fT > 1$ mg/L of 38.4%, while a 1-log10 kill required 63.6%.
  • For E. coli: Bacteriostasis required %$fT > 1$ mg/L of only 1.8%, and a 1-log10 kill required 40.1%.

Pralurbactam showed potent activity against a wide range of enzymes, particularly those producing OXA-48 and KPC. Interestingly, the targets for E. coli were lower than for K. pneumoniae, suggesting higher potency against certain NDM-producing strains.

Conclusion and Future Directions

This study provides essential PK/PD targets for the pralurbactam/meropenem combination. While promising, the authors note that interspecies scaling is necessary as mice eliminate drugs faster than humans. Future work may include lung infection models to better understand drug permeability in different tissues and testing against a broader array of NDM-producing strains where the combination currently shows partial inhibitory activity.

Summary updated

Abstract

These PK/PD data derived from mouse thigh infection models will be used to inform the optimal dosing regimen of pralurbactam/meropenem combination in clinical trials.
BibTeX
@inproceedings{huang2024pharmacokinetic,
  author = {Zhiwei Huang and Wenfang Li and Ruohao Zhang and Yi Li and Xin Li and Xingchen Bian and Shansong Zheng and Xinmei Wang and Ning Zhang and Gao Cong and Beining Guo and Zhenling Wang and Jing Zhang and Xiaojie Wu},
  title = {{Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model}},
  booktitle = {Frontiers in Microbiology},
  year = {2024},
  doi = {10.3389/fmicb.2024.1516979},
}
Figure